加藤晃史 (Terufumi Kato) - マイポータル

基本情報

所属: 地方独立行政法人東京都立病院機構東京都立駒込病院臨床研究・治験センター部長

学位: 医学学士(1991年3月京都大学)

研究者番号: 80728725
ORCID iD: https://orcid.org/0000-0002-5853-1424
J-GLOBAL ID: 202401005463604492
researchmap会員ID: R000079853

経歴

2025年9月 - 現在

地方独立行政法人東京都立病院機構東京都立駒込病院, 臨床研究・治験センター, 部長
2016年4月 - 2025年3月

神奈川県立がんセンター, 呼吸器内科, 医長
2008年4月 - 2016年3月

神奈川県立循環器呼吸器病センター, 呼吸器内科, 医長
2005年6月 - 2008年3月

国立がんセンター研究所, 計画治療支援施設
2003年6月 - 2005年5月

国立がんセンター中央病院, 肺内科
1996年6月 - 2003年5月

天理よろづ相談所病院, 呼吸器内科, 医員
1991年5月 - 1996年5月

天理よろづ相談所病院, 総合診療科, ジュニア/シニアレジデント

学歴

1985年4月 - 1991年3月

京都大学, 医学部, 医学科

論文

184

Safety and effectiveness of tepotinib in patients with unresectable, advanced or recurrent non-small cell lung cancer with METex14 skipping alterations: post-marketing surveillance in Japan

Terufumi Kato, Tatsuya Ogura, Masashi Sato, Risa Kojima, Bingbing Song, Eisuke Horii, Kazuhiko Nakagawa

Japanese Journal of Clinical Oncology 2025年10月7日
KEYNOTE‐A17: First‐Line Pembrolizumab Plus Cisplatin–Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma

Takashi Kijima, Terufumi Kato, Yasushi Goto, Kozo Kuribayashi, Koji Mikami, Yoshiki Negi, Shuji Murakami, Tatsuya Yoshida, Masae Homma, Akira Wakana …

Cancer Science 2025年8月
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.

Satoru Miura, Hiroshi Tanaka, Toshihiro Misumi, Hiroshige Yoshioka, Takaaki Tokito, Tatsuro Fukuhara, Yuki Sato, Yoshimasa Shiraishi, Katsuhiko Naoki, Hiroaki Akamatsu …

Journal of clinical oncology : official journal of the American Society of Clinical Oncology JCO2402007 2025年4月16日
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study

Marina Chiara Garassino, Yong He, Myung-Ju Ahn, Sergey V. Orlov, Vanessa Potter, Terufumi Kato, Janessa Laskin, Pei Jye Voon, Thanyanan Reungwetwattana, Suresh S. Ramalingam …

Lung Cancer 2025年4月
Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case-control study of abemaciclib-induced interstitial lung disease (NOSIDE).

Sayuka Nakayama, Ayuha Yoshizawa, Junji Tsurutani, Kenichi Yoshimura, Gaku Aoki, Takayuki Iwamoto, Hiroyuki Nagase, Naoya Sugimoto, Konomi Kobayashi, Shinyu Izumi …

Breast cancer (Tokyo, Japan) 2024年11月18日
The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

Jhanelle E Gray, Michael Schenker, Mehmet Ali Nahit Şendur, Viktoriya Leonova, Dariusz Kowalski, Terufumi Kato, Rashida Orlova, James Chih-Hsin Yang, Adrian Langleben, Arnold Pilz …

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2024年11月7日
Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study.

Hirotsugu Kenmotsu, Kazuko Sakai, Keita Mori, Terufumi Kato, Shunichi Sugawara, Keisuke Kirita, Yasuto Yoneshima, Koichi Azuma, Kazumi Nishino, Shunsuke Teraoka …

JTO clinical and research reports 5(11) 100716-100716 2024年11月
Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia.

Yuki Kato, Hibiki Udagawa, Shingo Matsumoto, Hiroki Izumi, Yuichiro Ohe, Terufumi Kato, Kazumi Nishino, Shingo Miyamoto, Sachiko Kawana, Kenichi Chikamori …

Lung cancer (Amsterdam, Netherlands) 197 107992-107992 2024年11月
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous Non-Small-Cell Lung Cancer That Responded to First-Line Pembrolizumab Plus Chemotherapy.

Maximilian Hochmair, Michael Schenker, Manuel Cobo Dols, Tae Min Kim, Ozgur Ozyilkan, Maria Smagina, Leonova Viktoriya, Terufumi Kato, Alexander Fedenko, Flavia De Angelis …

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2024年10月28日
Clinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib.

Shigeki Umemura, Hibiki Udagawa, Takaya Ikeda, Haruyasu Murakami, Haruko Daga, Ryo Toyozawa, Toshiyuki Kozuki, Jun Sakakibara-Konishi, Yuichiro Ohe, Masahiro Morise …

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2024年10月10日
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.

Jonathan D Spicer, Marina C Garassino, Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Ke-Neng Chen, Christophe Dooms, Margarita Majem …

Lancet (London, England) 404(10459) 1240-1252 2024年9月28日
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC.

Maximilian J Hochmair, Karim Vermaelen, Giannis Mountzios, Enric Carcereny, Christophe Dooms, Se-Hoon Lee, Eva Morocz, Terufumi Kato, Tudor-Eliade Ciuleanu, Grace K Dy …

European journal of cancer (Oxford, England : 1990) 208 114204-114204 2024年9月
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.

Shun Lu, Terufumi Kato, Xiaorong Dong, Myung-Ju Ahn, Le-Van Quang, Nopadol Soparattanapaisarn, Takako Inoue, Chih-Liang Wang, Meijuan Huang, James Chih-Hsin Yang …

The New England journal of medicine 391(7) 585-597 2024年8月15日
Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.

Shun Horaguchi, Yoshiro Nakahara, Yuka Igarashi, Taku Kouro, Feifei Wei, Kenta Murotani, Seiichi Udagawa, Naoko Higashijima, Norikazu Matsuo, Shuji Murakami …

Biomedicines 12(8) 2024年8月12日
Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND).

Daichi Fujimoto, Hidetoshi Hayashi, Kenta Murotani, Yukihiro Toi, Toshihide Yokoyama, Terufumi Kato, Teppei Yamaguchi, Kaoru Tanaka, Satoru Miura, Motohiro Tamiya …

Lung cancer (Amsterdam, Netherlands) 194 107896-107896 2024年8月
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.

Yi-Long Wu, Valentina Guarneri, Pei Jye Voon, Boon Khaw Lim, Jin-Ji Yang, Marie Wislez, Cheng Huang, Chong Kin Liam, Julien Mazieres, Lye Mun Tho …

The Lancet. Oncology 25(8) 989-1002 2024年8月
Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy" [Lung Cancer 177 (2023) 44-50].

Masayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, Kaname Nosaki, Yasutaka Watanabe, Terufumi Kato, Daisuke Hayakawa, Hiroshi Tanaka, Toshiaki Takahashi, Masahide Oki …

Lung cancer (Amsterdam, Netherlands) 193 107852-107852 2024年7月
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.

Terufumi Kato, James Chih-Hsin Yang, Myung-Ju Ahn, Hiroshi Sakai, Masahiro Morise, Yuh-Min Chen, Ji-Youn Han, Jin-Ji Yang, Jun Zhao, Te-Chun Hsia …

British journal of cancer 130(10) 1679-1686 2024年6月
Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia.

Masanobu Okahisa, Hibiki Udagawa, Shingo Matsumoto, Terufumi Kato, Hiroshi Yokouchi, Naoki Furuya, Ryota Kanemaru, Ryo Toyozawa, Akihiro Nishiyama, Kadoaki Ohashi …

Lung cancer (Amsterdam, Netherlands) 191 107798-107798 2024年5月
Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis.

Satoshi Ikeda, Takashi Ogura, Terufumi Kato, Hirotsugu Kenmotsu, Yoko Agemi, Takaaki Tokito, Kentaro Ito, Kohsuke Isomoto, Yuichi Takiguchi, Yasuto Yoneshima …

Annals of the American Thoracic Society 21(4) 635-643 2024年4月

もっとみる

MISC

MO19-2 INSIGHT2: Tepotinib + osimertinib in pts with EGFR-mutant NSCLC and acquired resistance to 1L osimertinib due to METamp

Masahiro Morise, Hiroshi Sakai, Terufumi Kato, Takaaki Tokito, Masayuki Takeda, Hiroshi Tanaka, Kenichi Chikamori, Haruko Daga, Takashi Kijima, Kadoaki Ohashi …

Annals of Oncology 32 S309-S309 2021年7月
Large scale clinico-genomic analyses among patients with BRAF-mutated non-small cell lung cancers (NSCLC) identified by nationwide genomic screening project (LC-SCRUM-Japan).

Tetsuya Sakai, Shingo Matsumoto, Taku Nakagawa, Kadoaki Ohashi, Hidetoshi Itani, Masato Shingyoji, Atsushi Nakamura, Ryo Toyozawa, Masahide Mori, Takeshi Tuda …

JOURNAL OF CLINICAL ONCOLOGY 38(15) 2020年5月
Therapeutic impact of mutation subtypes and concomitant STK11 mutations in KRAS-mutated non-small cell lung cancer (NSCLC): A result of nationwide genomic screening project (LC-SCRUM-Japan).

Yutaro Tamiya, Yochitaka Zenke, Shingo Matsumoto, Naoki Furuya, Tomohiro Sakamoto, Terufumi Kato, Kazumi Nishino, Masato Shingyoji, Shingo Miyamoto, Chigusa Shirakawa …

JOURNAL OF CLINICAL ONCOLOGY 38(15) 2020年5月
RELAY study of erlotinib (ERL) plus ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC): Biomarker analysis using circulating tumor DNA (ctDNA) in Japanese patients (pts).

Kazuto Nishio, Kazuko Sakai, Takashi Seto, Makoto Nishio, Edward B. Garon, Martin Reck, Koichi Goto, Terufumi Kato, Yoichi Nakanishi, Toshiaki Takahashi …

JOURNAL OF CLINICAL ONCOLOGY 38(15) 2020年5月
Clinical characteristics of nivolumab-induced radiation recall pneumonitis in patients with non-small cell lung cancer: A multicenter real-world analysis of 669 patients

Tadasuke Shimokawaji, Shoko Narita, Tomoyuki Naito, Hibiki Udagawa, Koichi Goto, Taichi Miyawaki, Nobuaki Mamesaya, Kazuhisa Nakashima, Hirotsugu Kenmotsu, Terufumi Kato …

JOURNAL OF CLINICAL ONCOLOGY 38(5) 2020年2月
Phase II study of osimertinib in patients with plasma EGFR T790M positive advanced lung cancer (WJOG8815L/LPS)

Takayuki Takahama, Koichi Azuma, Mototsugu Shimokawa, Terufumi Kato, Haruko Daga, Isamu Okamoto, Hiroaki Akamatsu, Toshiaki Takahashi, Tatsuo Ohira, Toshihide Yokoyama …

ANNALS OF ONCOLOGY 29 2018年10月
Contribution of nationwide genome screening in Japan (LC-SCRUM-Japan) to the development of precision medicine for non-small cell lung cancer.

Takashi Seto, Shingo Matsumoto, Kiyotaka Yoh, Yutaka Fujiwara, Takuma Yokoyama, Kazumi Nishino, Terufumi Kato, Shunichi Sugawara, Masato Shingoji, Masahiro Kodani …

JOURNAL OF CLINICAL ONCOLOGY 36(15) 2018年5月
Combined Safety Analysis for Japanese in Domestic Phase 1, Phase 1b and International Phase 2/3 Trials of Pembrolizumab

Atsushi Horiike, Hideo Saka, Hiroshi Tanaka, Terufumi Kato, Naoya Yamazaki, Kazuhiko Yamada, Kenji Yokota, Shunichi Sugawara, Kazuo Noguchi, Hidetoshi Hayashi

ANNALS OF ONCOLOGY 28 2017年10月
Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors for fatal outcome.

Terufumi Kato, Fumikazu Sakai, Tomohisa Baba, Masahiko Kusumoto, Hirotsugu Kenmotsu, Hiroaki Sugiura, Junya Tominaga, Katsunori Oikado, Masafumi Sata, Masahiro Endo …

JOURNAL OF CLINICAL ONCOLOGY 35 2017年5月
Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (TORG1018).

Kaoru Kubota, Tsuneo Shimokawa, Kazuhiko Yamada, Hiroshi Tanaka, Kazuma Kishi, Haruhiro Saito, Yuichi Takiguchi, Yukio Hosomi, Terufumi Kato, Naoyuki Nogami …

JOURNAL OF CLINICAL ONCOLOGY 35 2017年5月
Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors using interim results of post-marketing all-case surveillance.

Hirotsugu Kenmotsu, Fumikazu Sakai, Terufumi Kato, Masahiko Kusumoto, Tomohisa Baba, Kazuyoshi Kuwano, Akihiko Gemma, Kazuhiko Nakagawa, Yoichi Nakanishi, Nobuyuki Yamamoto …

JOURNAL OF CLINICAL ONCOLOGY 35 2017年5月
A Randomized Phase II Trial of S-1 plus Cisplatin or Docetaxel plus Cisplatin with Concurrent Thoracic Radiotherapy for Stage III NSCLC: TORG1018

Kazuhiko Yamada, Tsuneo Shimokawa, Hiroaki Okamoto, Hiroshi Tanaka, Kaoru Kubota, Kazuma Kishi, Haruhiro Saito, Yuichi Takiguchi, Yukio Hosomi, Terufumi Kato …

JOURNAL OF THORACIC ONCOLOGY 12(1) S863-S863 2017年1月
Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged >= 65 Years: Subgroup Analysis of LUX-Lung 3/6

Luis Fein, Yi-Long Wu, Lecia V. Sequist, Sarayut L. Geater, Sergey Orlov, Ki Hyeong Lee, Chun-Ming Tsai, Terufumi Kato, Katsuyuki Kiura, Carlos H. Barrios …

JOURNAL OF THORACIC ONCOLOGY 11(10) S202-S203 2016年10月
Randomized PII Trial Comparing CDDP/TS1 With CDDP/DTX With Concurrent Radiotherapy in Locally Advanced NSCLC (TORG1018)

Haruhiro Saito, Hiroshi Tanaka, Tsuneo Shimokawa, Hiroaki Okamoto, Kazuhiko Yamada, Kaoru Kubota, Kazuma Kishi, Yuichi Takiguchi, Yukio Hosomi, Terufumi Kato …

ANNALS OF ONCOLOGY 27 2016年7月
Development of a nationwide genomic screening network for squamous cell lung cancer in Japan (LC-SCRUM-Japan).

Tadasuke Shimokawaji, Eri Sugiyama, Shingo Matsumoto, Kiyotaka Yoh, Masato Shingyoji, Kadoaki Ohashi, Terufumi Kato, Hiromi Aono, Yuichiro Ohe, Shunichi Sugawara …

JOURNAL OF CLINICAL ONCOLOGY 34(15) 2016年5月
Phase II study of carboplatin plus weekly nab-paclitaxel in elderly patients with NSCLC:NJLCG1301

Kazuhiro Usui, Eisaku Miyauchi, Shunichi Sugawara, Tatsuro Fukuhara, Heisuke Saito, Yuka Fujita, Terufumi Kato, Toshiro Suzuki, Akira Inoue, Masakazu Ishinose

ANNALS OF ONCOLOGY 26 92-92 2015年11月
Phase II Study of Carboplatin plus Weekly Nab-Paclitaxel in Elderly Patients with NSCLC: North Japan Lung Cancer Study Group Trial 1301

Osamu Ishimoto, Kazuhiro Usui, Makoto Maemondo, Eisaku Miyauchi, Heisuke Saito, Yuka Fujita, Terufumi Kato, Toshiro Suzuki, Taku Nakagawa, Toshiyuki Harada …

JOURNAL OF THORACIC ONCOLOGY 10(9) S657-S658 2015年9月
Randomized Phase III Study of Nedaplatin plus Docetaxel versus Cisplatin plus Docetaxel for Advanced Squamous Cell Lung Cancer (WJOG5208L)

Takashi Seto, Takehito Shukuya, Takeharu Yamanaka, Tomonori Hirashima, Terufumi Kato, Yoshitsugu Horio, Shinji Atagi, Takako Inoue, Yoshinobu Ohsaki, Tadashi Maeda …

JOURNAL OF THORACIC ONCOLOGY 10(9) S173-S173 2015年9月
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial

Terufumi Kato, Takashi Seto, Makoto Nishio, Koichi Goto, Shinji Atagi, Yukio Hosomi, Noboru Yamamoto, Toyoaki Hida, Makoto Maemondo, Kazuhiko Nakagawa …

JOURNAL OF CLINICAL ONCOLOGY 32(15) 2014年5月
NEJ009 trial: A randomized phase III study of gefitinib (G) on combination with carboplatin (C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutation

Akira Inoue, Yukio Hosomi, Makoto Maemondo, Shunichi Sugawara, Terufumi Kato, Kazuhlsa Takahashi, Yuka Fujita, Aklhlko Gamma, Toshiyuki Harada, Satoshi Oizumi …

JOURNAL OF CLINICAL ONCOLOGY 32(15) 2014年5月

もっとみる

加藤晃史

基本情報

経歴

学歴

論文

MISC

メニュー

共著者の一覧